Nobody Tells You What GLP-1s Do to Your Sex Drive | GLS #213

Lyon stresses that subjective feelings ('something's off') are unreliable. The validated instruments convert experience into a quantifiable score that can be tracked over time, analogous to tracking weight or HbA1c. She notes that these tools take 5 minutes and that researchers use them, but they are rarely, if ever, deployed in routine GLP-1 follow-up. She frames this as a vital sign that ought to be part of standard care but currently isn't, and suggests patients advocate for it themselves.

Lyon describes SHBG as a 'sponge' and notes that clinicians often order only total testosterone. A man who loses 30 lbs may feel sexually flat even with a 'normal' total T because his free T has been sequestered. For women, who start with a fraction of male levels, the same sequestration can push free T below a threshold needed for desire and arousal. She emphasizes that this is a predictable consequence of rapid weight loss, not idiosyncratic to the drug, but that GLP-1s cause rapid weight loss, so the effect is common among users.

Lyon connects this advice to the broader conversation by arguing that muscle loss and sexual dysfunction share a root: the loss of tissue needed for function. The reduced appetite from GLP-1s increases the risk of sarcopenia if protein isn't intentionally front-loaded. She references her own peer-reviewed paper on sexual function and muscle mass, indicating that resistance training improves blood flow, hormone signaling, and lean mass preservation—all of which directly support sexual health. She frames these two practices as the highest-confidence interventions (tier 1) because they address the muscle-metabolism axis that underpins many of the drug’s indirect negative effects.

Lyon positions dose reduction as the first-line response because dose-response curves often mean that a lower dose preserves some metabolic benefit while reducing the intensity of side effects. She recommends a 6-8 week trial at the reduced dose before concluding that the drug class is problematic for that individual.

Lyon bases this protocol on the Cleveland Clinic case: a woman who lost orgasmic function on liraglutide and did not improve on semaglutide, but regained it on tirzepatide. She also cites the 2026 side-effect profile study finding semaglutide stood out for menstrual and depression signals while tirzepatide did not. She calls it 'hypothesis level, not guideline level,' but frames it as a reasonable conversation to have with a doctor before abandoning the class altogether, given the metabolic benefits at stake.

Lyon frames this as a tier-2 recommendation that targets a peripheral, tissue-level problem rather than the central nervous system dampening. She explains that while it won't fix the reward-circuit issue, it can make sex physically comfortable again, which may indirectly improve the overall sexual experience.

Lyon lists this under tier 3 (experimental/low confidence) because adding testosterone on top of a GLP-1 has no trial data in this specific population. She emphasizes the fertility trade-off: unlike GLP-1s which preserve FSH and LH, testosterone therapy shuts down the hypothalamic-pituitary-gonadal axis. For a young man wanting children, this distinction is critical. She notes that in some head-to-head data, the GLP-1 liraglutide actually matched or beat testosterone injections for improving erectile function, so adding testosterone may be unnecessary in many cases.

Lyon frames the confidence scale as an antidote to over-certainty. At 95% confidence she says GLP-1s improve sexual function in men with obesity and metabolic disease—multiple study types converge. At 90% she’s confident the drugs dampen brain reward beyond appetite (the reason they’re studied for addiction). At 80% she believes the net effect is population-dependent: in a man with obesity, metabolic benefits outweigh reward dampening; in a lean woman or postmenopausal woman, there is no metabolic deficit to fix, so the dampening and vascular/hormonal changes can tip the scales negative. At 70% she asserts women are experiencing a missed signal because nobody is measuring it—zero pivotal trials used a validated sexual function questionnaire with women. At 60% she attributes the potential female harm to combined vascular tightening, central dopamine dampening, and SHBG-driven free testosterone drop from rapid weight loss, but stresses the mechanisms are inferred, not directly tested. At 55% she says different GLP-1 drugs may have meaningfully different sexual/psychiatric profiles, citing a 2026 pharmacovigilance study where semaglutide stood out for menstrual and depression signals while tirzepatide did not, despite greater weight loss. Finally, below 30% confidence she predicts no proper studies within 2 years unless patients demand them.

Lyon traces the mechanistic logic: GLP-1 receptors sit in the gut, pancreas, brain reward system, blood vessels, and smooth muscle. Every GLP-1 drug hits this same receptor. In a man with obesity-related hypogonadism, weight loss reduces aromatase activity in fat tissue (less testosterone-to-estrogen conversion), improves endothelial function, lowers inflammation, and raises testosterone. Simultaneously, the drug leaves LH and FSH intact, preserving sperm production—the opposite of testosterone replacement therapy. These forces combine into a net positive. For a lean woman or a postmenopausal woman whose sexual function was normal, however, there’s no obesity-driven hormonal or vascular deficit to correct. Yet the drug’s reward dampening still operates, blood vessels in genital tissue can constrict, and rapid weight loss raises SHBG, which sponges up free testosterone that was already low. Without the offsetting upside, the net can become negative. The case isn't about which specific GLP-1 agonist, but which body is hosting the receptor.

Lyon uses the metaphor of a 'sponge' that soaks up testosterone. She notes that a man can lose 30 lb, see a normal total testosterone number, and still feel sexually flat because free testosterone has dropped without being measured. For women, who have a fraction of the testosterone men do, even a small SHBG rise can push free testosterone into a clinically meaningful deficit. She stresses that there is no standard protocol for checking this, and that she has seen 'the majority' of her female patients have lower testosterone, making the drop especially consequential.

Lyon compares the situation to a dark room with no light switch: 'We called a darkened room empty.' The trials meticulously tracked weight, glucose, and cardiovascular outcomes but never asked about sexual function. She contrasts this with the systematic efforts to study these drugs for alcohol and gambling addiction—reward dampening is openly acknowledged, but the downstream impact on sexual reward in women remains unexamined. The episode urges patients to demand the measurement, because pharmacovigilance alone (FAERS captures only 1-10% of side effects, and sexual ones are among the most underreported) will not fill the gap.

Lyon cites a 2026 study comparing six GLP-1 drugs. Semaglutide stood out with higher reporting for menstrual abnormalities and depression in two separate international databases, while tirzepatide (which adds GIP agonism) did not. She notes that semaglutide’s market dominance could generate more reports, but tirzepatide is also widely used and doesn't show the same signal. She places her confidence at 55%—just above a coin flip—because pharmacovigilance can't prove causation. Still, she uses this as a rationale for considering a switch from semaglutide to tirzepatide when sexual side effects emerge, referencing a Cleveland Clinic case where a woman regained orgasmic function after switching to tirzepatide.